AFFiRiS granted new patent in China for treating Parkinson’s disease

Must Read

How To Block Your Bank Account And SIM Card In Case Of Emergency

Losing your phone and wallet or having them stolen can be very frustrating. However, in case that happens to...

List of United Bank for Africa (UBA) Sort Codes & Branches (with addresses) in Nigeria

The sort code is a number that usually identifies both the bank and the branch where an account is held. The sort...

FG, States, LGAs share N528.39bn FAAC allocation in Jan 2021

The Federation Account Allocation Committee (FAAC) disbursed the sum of N619.34bn to the three tiers of government in December...
- Advertisement -

Patent adds to company’s robust portfolio covering clinical stage lead development candidate PD01

 

VIENNA, AUSTRIA – EQS Newswire – March 3, 2020 – AFFiRiS, a
clinical-stage biotechnology company developing novel disease-modifying
specific active immunotherapies (SAITs) for patients with neurodegenerative
diseases, today announces the award of a new patent by the Chinese National
Intellectual Property Administration (CNIPA). The patent covers a group of
AFFITOPEs, including PD01, the Company’s lead candidate for the treatment of
early-stage Parkinson’s disease patients which is expected to enter clinical
phase 2 in the second half of 2020.

 

AFFiRiS, which has already
obtained patents in the United States, Europe, Australia, Canada, India, Japan
and South Korea for the same application, thus further expand the geographic
coverage of its intellectual property portfolio thanks to this new patent. In
addition, the newly granted IP adds to AFFiRiS’ broad patent position covering
the treatment of Parkinson’s disease, and its product candidate PD01, as well
as to its overall body of patents and patent applications, reflecting the
excellent competitive profile in the field of neurodegenerative treatments.

- Advertisement -

 

“This new patent
strengthens the position of our lead candidate, PD01, which we will move into
phase 2 of clinical development for the treatment Parkinson’s disease, an
indication with an urgent and significant unmet medical need,” said Noel
Barrett, Ph.D., AFFiRiS’ Chief Executive Officer. “Importantly, the new IP
supports us in the growth of our business in the highly attractive Chinese
market.”

 

AFFiRiS recently received
positive FDA responses to its pre-Investigational New Drug (“IND”)
submission for the phase 2 trial with AFFITOPE(R) PD01 in early Parkinson’s
disease patients. The active immunotherapy candidate PD01 is based on AFFiRiS’
AFFITOPE(R) technology, which is also covered by this new patent.

- Advertisement -

 

The new patent CN 101969989
(also published as WO 2009/103105) describes how AFFiRiS’ AFFITOPE(R) compounds
may prevent and/or treat neurodegenerative disorders characterized by
pathological accumulation of alpha-synuclein aggregates, commonly referred to
as synucleinopathies, including Parkinson’s disease (PD), Parkinson’s disease
with dementia (PDD) and dementia with Lewy bodies (DLB), as well as Multiple
System Atrophy (MSA) or Neurodegeneration with Brain Iron Accumulation type I
(NBIA Type I).

 

The issuer is solely responsible for the content of this announcement.

- Advertisement -

About AFFITOPE(R) PD01:

AFFITOPE(R) PD01 is a synthetically produced alpha-synuclein
(aSyn)-mimicking peptide based specific active immunotherapy (SAIT) that
targets the protein aSyn, which plays a key role in the onset and progression
of Parkinson’s Disease. In a phase 1 study program, early Parkinson patients
were observed for up to 48 months with regard to long-term safety,
immunological and clinical parameters. The immunotherapy candidate was
demonstrated to be well tolerated. AFFITOPE(R) PD01 induced a long lasting
humoral immune response that could be reactivated upon booster application.
Clinical scores for PD were stable during the entire study period in the PD01
treated group, however, the study was not designed and not powered to evaluate
clinical efficacy. The phase 1 studies were supported by The Michael J. Fox
Foundation for Parkinson’s Research.


Read Also:  Burkhard Eling takes up role of CEO at Dachser

About Parkinson’s disease:

Parkinson’s disease (PD) is the second most common
neurodegenerative disorder after Alzheimer’s disease and the most common
neurodegenerative movement disease. It affects approximately 1 % of the
population above the age of 60, about 7-10 million people worldwide. PD is a
chronic progressive disorder, defined by a combination of motoric and
non-motoric syndromes. The hallmark of the disease is a substantial loss of
dopaminergic neurons in the brain accompanied by accumulations of filamentous
protein inclusions predominantly composed of alpha Synuclein (aSyn). Evidence
suggests that the misfolding of the aSyn protein causes inflammation, synaptic
dysfunction and finally neuronal cell death. Current therapies target symptoms
but fail to modify the underlying neurodegeneration. In addition, these
therapies result in varying degrees of side effects, and their beneficial
effects are diminishing over time.


About AFFiRiS AG:

AFFiRiS is a clinical-stage biotechnology company located in
Vienna, Austria, that pursues the vision of using the immune system to identify
and target human proteins central to the development and progression of
neurodegenerative diseases, based on its proprietary patented AFFITOME(R)
technology. The ultimate aim is to improve the lives of patients suffering from
these diseases by providing disease-modifying specific active immunotherapies
(SAIT). With its lead candidate AFFITOPE(R) PD01 AFFiRiS is the leader in
active immunotherapies for Parkinson’s disease. In addition, AFFiRiS’ programs
against multiple system atrophy, dementia with Lewy bodies, and chorea
Huntington are in pre-clinical development. For further information, please
visit www.affiris.com and
follow us on LinkedIn and Twitter.

About SAIT:
https://affiris.com/approach/#overview-of-sait

About neurodegenerative
diseases:

https://affiris.com/neurodegenerative-diseases/

About Parkinson’s disease:
https://affiris.com/neurodegenerative-diseases/#parkinsons-disease

AFFiRiS granted new patent in China for treating Parkinson's disease - Brand Spur

- Advertisement -
AFFiRiS granted new patent in China for treating Parkinson's disease - Brand SpurAFFiRiS granted new patent in China for treating Parkinson's disease - Brand Spur

Subscribe to BrandSpur Ng

Subscribe for latest updates. Signup to best of brands and business news, informed analysis and opinions among others that can propel you, your business or brand to greater heights.

- Advertisement -

LEAVE A REPLY

Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.

AFFiRiS granted new patent in China for treating Parkinson's disease - Brand SpurAFFiRiS granted new patent in China for treating Parkinson's disease - Brand Spur

Latest News

Cityneon Raises S$235 Million; Well Positioned for Next Growth Chapter

  • The global experience entertainment company gets a S$235 million shot in the arm, closes its private fund raising in April 2021
  • Investors both new and existing include Singapore's Pavilion Capital, Seatown Holdings International and EDBI, Qatar's Doha Venture Capital and financial institutions and family offices in Singapore and China
  • These now join other existing Cityneon shareholders CITIC Capital, veteran entrepreneur and investor Mr. Johnson Ko, and Executive Chairman & Group CEO Mr. Ron Tan
  • Funding comes just after the Group acquired multi-year licensing rights for James Cameron's AVATAR touring exhibition, and two original artefacts IP on the ancient civilization Machu Picchu from Peru and Ramses the Great (Ramses II) from Egypt
  • Investments position the Group well to bring experiences across the globe, targeting to launch six experiences in China and five in the U.S. by the end of 2021, with more in other parts of the world
Read Also:  Global eTrade Services introduces new finance services suite on CALISTA™; to reinforce end-to-end supply chain orchestration

SINGAPORE - Media OutReach - 21 April 2021 - Cityneon Holdings ("Cityneon", the "Company"/collectively with its subsidiaries, the "Group") raised S$235 million in the most recent round of private funding. The latest round of funding adds seasoned investors to Cityneon's already strong stable of shareholders.

This funding round was led by Singapore's Pavilion Capital, Seatown Holdings International, EDBI, and Cityneon's Executive Chairman & Group CEO, Mr. Ron Tan. EDBI and Pavilion Capital are existing shareholders of Cityneon whilst new investors include Seatown Holdings International, Qatar's Doha Venture Capital, which will now own approximately 4 per cent of the Group, and other financial institutions and family offices in Singapore and China.

These now join other existing Cityneon shareholders CITIC Capital, veteran entrepreneur and investor Mr. Johnson Ko, and Executive Chairman & Group CEO Mr. Ron Tan to form a new and strong shareholder base for the Group. Mr. Johnson Ko and Mr. Ron Tan remain as the largest shareholders of the company via their combined entity, West Knighton Limited.

The Group is now well positioned for its next growth chapter and will use the proceeds for capital expenditure that includes building more of its various intellectual property (IP) exhibition sets, totaling 24 travelling and four semi-permanent sets under the Studio IP partnerships and three travelling sets under the original artefact IP partnerships by the end of 2022.

Already, the Group just signed its fifth IP rights with Avatar from 20th Century Studios last year. Amidst the anticipation from Avatar fans worldwide, Cityneon will debut a multi-sensory Avatar exhibition in Chengdu, China in May 2021, ahead of the Avatar movie sequel which is slated for release in 2022. Avatar is the world's top grossing film of all time at over US$2.8 billion, and adding millions more after its successful re-release in China in March 2021. Avatar's director James Cameron has announced that he will be producing four sequels with 20th Century Studios, with the first sequel slated for release next year. Disney acquired 20th Century Studios for US$71 billion in 2019.

The Company also recently entered the original artefacts IPs space and will stage international exhibitions of the treasures of the ancient civilization Machu Picchu from Peru in Boca Raton, Florida and Pharaoh Ramses II from Egypt in Houston, Texas. These two experiences will start welcoming visitors in October and November 2021, respectively.

Other IP rights that the Group holds include partnerships with Universal Studios for Jurassic World: The Exhibition, Marvel for Avengers S.T.A.T.I.O.N., Lionsgate for The Hunger Games: The Exhibition and Hasbro for Transformers Autobot Alliance. All in, Cityneon holds the IP rights for five of the top 10 worldwide box office hits and two artefacts IP from Peru and Egypt. The Group expects to have six sets of its various IP rights travelling across China, and five travelling and permanent sets in the United States, with a few more in other parts of the globe.

The Group will also be reopening experiences that were temporarily closed in 2020, aiming to provide visitors with a safe entertainment option. These include the Marvel Avengers S.T.A.T.I.O.N. in Toronto, Canada that will be re-opening in May 2021; and the Marvel Avengers S.T.A.T.I.O.N. exhibition in Lotte Mall in Seoul, Korea in April 2021; the same exhibition space which previously housed Jurassic World: The Exhibition, another IP experience exhibition by the Group in 2019. In the past month, the Group also witnessed record visitor numbers at their semi-permanent installations in Las Vegas, USA, signaling a strong comeback and demand for their immersive experiences, as they step into the 6th year of operations there.

While there are exciting plans lined up, the Group is not resting on its laurels. More Hollywood IPs and artefact IPs can be expected, and there will be further announcements on new IP verticals in entertainment experiences that the Group is looking to enter.

Mr. Ron Tan, Executive Chairman & Group CEO of Cityneon, said: "It is exciting that the Company is going through such strategic expansion as one of the largest providers of exhibition entertainment experiences globally. The S$235 million funding round sets a solid foundation for us to invest in developing more of our entertainment experiences, to stage even more exhibitions of the five box office hits and two artefact IPs that we hold the rights to all over the world. I'm thankful that our strong investors base, now from Singapore, Hong Kong, China and the Middle East, have trust in our vision, and believe alongside us that this space of big ideas and big experiences will only grow."

By the end of this year, Cityneon will arguably be the largest provider of exhibition entertainment experiences internationally; with global footprints in more than 50 cities and welcoming 10 million unique visitors across the world by 2022.

Cityneon Holdings

With its global reach and international partnerships, Cityneon has the capability to serve its clients anywhere in the world. Cityneon was listed on the Mainboard of the Singapore Stock Exchange since 2005, and was privatized on February 2019 by West Knighton Limited, a company wholly owned by Cityneon's Executive Chairman and Group CEO, Ron Tan, together with Hong Kong veteran entrepreneur and investor, Johnson Ko Chun Shun. Johnson is a capital markets veteran and has held controlling interests and directorships in many listed companies. In May 2019, Cityneon welcomed CITIC Capital as a new shareholder, who holds approximately 10% shares in Cityneon. CITIC Capital is part of CITIC Group, one of China's largest conglomerates, and has over US$25b of assets under its management across 100 funds and investment products globally. Other institutional shareholders of the Group include EDBI - a Singapore government-linked global investor, and Pavilion Capital - a Singapore-based investment institution which focuses on private equity investments, that made strategic investments in August and October 2019 respectively, to support the Group's further expansion globally. For more information, please visit www.cityneongroup.com.


AFFiRiS granted new patent in China for treating Parkinson's disease - Brand SpurFacebook | AFFiRiS granted new patent in China for treating Parkinson's disease - Brand SpurYoutube | AFFiRiS granted new patent in China for treating Parkinson's disease - Brand SpurLinkedIn | AFFiRiS granted new patent in China for treating Parkinson's disease - Brand SpurInstagram | AFFiRiS granted new patent in China for treating Parkinson's disease - Brand SpurToutiao | AFFiRiS granted new patent in China for treating Parkinson's disease - Brand SpurYouku

AFFiRiS granted new patent in China for treating Parkinson's disease - Brand SpurWeibo | Wechat:

AFFiRiS granted new patent in China for treating Parkinson's disease - Brand Spur


AFFiRiS granted new patent in China for treating Parkinson's disease - Brand Spur
- Advertisement -
BrandsPur Weekly Cartoons
- Advertisement -AFFiRiS granted new patent in China for treating Parkinson's disease - Brand SpurAFFiRiS granted new patent in China for treating Parkinson's disease - Brand Spur